132 related articles for article (PubMed ID: 19299905)
1. Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study.
Takano M; Kato M; Yoshikawa T; Sasaki N; Hirata J; Furuya K; Takahashi M; Yokota H; Kino N; Horie K; Goto T; Fujiwara K; Ishii K; Kikuchi Y; Kita T
Oncology; 2009; 76(5):315-21. PubMed ID: 19299905
[TBL] [Abstract][Full Text] [Related]
2. Correlation of UGT1A1 and ERCC1 gene polymorphisms with the outcome of combined irinotecan plus cisplatin treatment in recurrent ovarian cancer.
Xu Q; Ding YY; Song LX; Xu JF
Genet Mol Res; 2015 Jun; 14(2):7241-7. PubMed ID: 26125934
[TBL] [Abstract][Full Text] [Related]
3. [Study of irinotecan-induced toxicity and its correlation to UGT1A1 gene promoter polymorphisms].
Li H; Huang H; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2011 Dec; 46(12):888-91. PubMed ID: 22333276
[TBL] [Abstract][Full Text] [Related]
4. Recurrent cervical cancer in a patient who was compound heterozygous for UGT1A1*6 and UGT1A1*28 presenting with serious adverse events during irinotecan hydrochloride/nedaplatin therapy.
Takatori E; Shoji T; Miura Y; Takeuchi S; Yoshizaki A; Sugiyama T
J Obstet Gynaecol Res; 2013 Aug; 39(8):1354-8. PubMed ID: 23800356
[TBL] [Abstract][Full Text] [Related]
5. UGT1A1 genotype-specific phase I and pharmacokinetic study for combination chemotherapy with irinotecan and cisplatin: a Saitama Tumor Board study.
Takano M; Goto T; Hirata J; Furuya K; Horie K; Takahashi M; Yokota H; Kino N; Kudoh K; Kikuchi Y
Eur J Gynaecol Oncol; 2013; 34(2):120-3. PubMed ID: 23781580
[TBL] [Abstract][Full Text] [Related]
6. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy.
Massacesi C; Terrazzino S; Marcucci F; Rocchi MB; Lippe P; Bisonni R; Lombardo M; Pilone A; Mattioli R; Leon A
Cancer; 2006 Mar; 106(5):1007-16. PubMed ID: 16456808
[TBL] [Abstract][Full Text] [Related]
7. Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens.
Yang C; Liu Y; Xi WQ; Zhou CF; Jiang JL; Ma T; Ye ZB; Zhang J; Zhu ZG
Drug Des Devel Ther; 2015; 9():3677-83. PubMed ID: 26229432
[TBL] [Abstract][Full Text] [Related]
8. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.
Ando Y; Saka H; Ando M; Sawa T; Muro K; Ueoka H; Yokoyama A; Saitoh S; Shimokata K; Hasegawa Y
Cancer Res; 2000 Dec; 60(24):6921-6. PubMed ID: 11156391
[TBL] [Abstract][Full Text] [Related]
9. A modified shortened administration schedule for neoadjuvant chemotherapy with irinotecan and cisplatin in locally advanced cervical cancer.
Ren Y; Li Y; Liu J
Int J Gynecol Cancer; 2011 May; 21(4):685-9. PubMed ID: 21543932
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin.
Han JY; Lim HS; Shin ES; Yoo YK; Park YH; Lee JE; Jang IJ; Lee DH; Lee JS
J Clin Oncol; 2006 May; 24(15):2237-44. PubMed ID: 16636344
[TBL] [Abstract][Full Text] [Related]
11. Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms.
Deng B; Jia L; Tan H; Lou Y; Li X; Li Y; Yu L
J Tradit Chin Med; 2017 Feb; 37(1):35-42. PubMed ID: 29956901
[TBL] [Abstract][Full Text] [Related]
12. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.
Liu CY; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
Cancer; 2008 May; 112(9):1932-40. PubMed ID: 18300238
[TBL] [Abstract][Full Text] [Related]
13. Impact of UGT1A1 genotype upon toxicities of combination with low-dose irinotecan plus platinum.
Takano M; Yamamoto K; Tabata T; Minegishi Y; Yokoyama T; Hirata E; Ikeda T; Shimada M; Yamada K; Morita S; Ando Y; Hirata K; Sugihara M; Sugiyama T; Ohashi Y; Sakata Y
Asia Pac J Clin Oncol; 2016 Jun; 12(2):115-24. PubMed ID: 26862009
[TBL] [Abstract][Full Text] [Related]
14. Phase II and UGT1A1 Polymorphism Study of Two Different Irinotecan Dosages Combined with Cisplatin as First-Line Therapy for Advanced Gastric Cancer.
Wang W; Huang J; Tao Y; Lyu X; Yang L; Wu D; Tian Y
Chemotherapy; 2016; 61(4):197-203. PubMed ID: 26872008
[TBL] [Abstract][Full Text] [Related]
15. Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer.
Otsuka H; Fujii T; Toh U; Iwakuma N; Takahashi R; Mishima M; Takenaka M; Kakuma T; Tanaka M; Shirouzu K
Breast Cancer; 2015 Jul; 22(4):335-42. PubMed ID: 23827973
[TBL] [Abstract][Full Text] [Related]
16. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan.
Carlini LE; Meropol NJ; Bever J; Andria ML; Hill T; Gold P; Rogatko A; Wang H; Blanchard RL
Clin Cancer Res; 2005 Feb; 11(3):1226-36. PubMed ID: 15709193
[TBL] [Abstract][Full Text] [Related]
17. A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies.
Sharma MR; Joshi SS; Karrison TG; Allen K; Suh G; Marsh R; Kozloff MF; Polite BN; Catenacci DVT; Kindler HL
Cancer; 2019 May; 125(10):1629-1636. PubMed ID: 30645764
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A).
Fukuda M; Shimada M; Kitazaki T; Nagashima S; Hashiguchi K; Ebi N; Takayama K; Nakanishi Y; Semba H; Harada T; Seto T; Okamoto I; Ichinose Y; Sugio K
Thorac Cancer; 2017 Jan; 8(1):40-45. PubMed ID: 27883280
[TBL] [Abstract][Full Text] [Related]
19. Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities.
Fakih MG; Ross ME; Starostik P
Clin Colorectal Cancer; 2007 Jul; 6(8):583-7. PubMed ID: 17681105
[TBL] [Abstract][Full Text] [Related]
20. UGT1A1 polymorphism as a prognostic indicator of stage I ovarian clear cell carcinoma patients treated with irinotecan.
Yoshihama T; Hirasawa A; Nomura H; Akahane T; Nanki Y; Yamagami W; Kataoka F; Tominaga E; Susumu N; Mushiroda T; Aoki D
Jpn J Clin Oncol; 2017 Feb; 47(2):170-174. PubMed ID: 28173214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]